Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry.
Defibrillators, Implantable
Electric Countershock
/ methods
Electrocardiography
Europe
/ epidemiology
Female
Follow-Up Studies
Heart Failure
/ epidemiology
Humans
Male
Middle Aged
Morbidity
/ trends
Prospective Studies
Registries
Risk Assessment
/ methods
Stroke Volume
/ physiology
Time Factors
Ventricular Function, Left
/ physiology
Heart failure
Implantable cardioverter-defibrillator
Sudden cardiac death
Wearable cardioverter-defibrillator
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
16
11
2019
accepted:
25
04
2020
pubmed:
8
5
2020
medline:
18
8
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
The prospective WEARIT-II-EUROPE registry aimed to assess the value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in patients with heart failure and reduced ejection fraction considered at risk of sudden arrhythmic death. 781 patients (77% men; mean age 59.3 ± 13.4 years) with heart failure and reduced left ventricular ejection fraction (LVEF) were consecutively enrolled. All patients received a WCD. Follow-up time for all patients was 12 months. Mean baseline LVEF was 26.9%. Mean WCD wearing time was 75 ± 47.7 days, mean daily WCD use 20.3 ± 4.6 h. WCD shocks terminated 13 VT/VF events in ten patients (1.3%). Two patients died during WCD prescription of non-arrhythmic cause. Mean LVEF increased from 26.9 to 36.3% at the end of WCD prescription (p < 0.01). After WCD use, ICDs were implanted in only 289 patients (37%). Forty patients (5.1%) died during follow-up. Five patients (1.7%) died with ICDs implanted, 33 patients (7%) had no ICD (no information on ICD in two patients). The majority of patients (75%) with the follow-up of 12 months after WCD prescription died from heart failure (15 patients) and non-cardiac death (15 patients). Only three patients (7%) died suddenly. In seven patients, the cause of death remained unknown. Mortality after WCD prescription was mainly driven by heart failure and non-cardiovascular death. In patients with HFrEF and a potential risk of sudden arrhythmic death, WCD protected observation of LVEF progression and appraisal of competing risks of potential non-arrhythmic death may enable improved selection for beneficial ICD implantation.
Sections du résumé
BACKGROUND
BACKGROUND
The prospective WEARIT-II-EUROPE registry aimed to assess the value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in patients with heart failure and reduced ejection fraction considered at risk of sudden arrhythmic death.
METHODS AND RESULTS
RESULTS
781 patients (77% men; mean age 59.3 ± 13.4 years) with heart failure and reduced left ventricular ejection fraction (LVEF) were consecutively enrolled. All patients received a WCD. Follow-up time for all patients was 12 months. Mean baseline LVEF was 26.9%. Mean WCD wearing time was 75 ± 47.7 days, mean daily WCD use 20.3 ± 4.6 h. WCD shocks terminated 13 VT/VF events in ten patients (1.3%). Two patients died during WCD prescription of non-arrhythmic cause. Mean LVEF increased from 26.9 to 36.3% at the end of WCD prescription (p < 0.01). After WCD use, ICDs were implanted in only 289 patients (37%). Forty patients (5.1%) died during follow-up. Five patients (1.7%) died with ICDs implanted, 33 patients (7%) had no ICD (no information on ICD in two patients). The majority of patients (75%) with the follow-up of 12 months after WCD prescription died from heart failure (15 patients) and non-cardiac death (15 patients). Only three patients (7%) died suddenly. In seven patients, the cause of death remained unknown.
CONCLUSIONS
CONCLUSIONS
Mortality after WCD prescription was mainly driven by heart failure and non-cardiovascular death. In patients with HFrEF and a potential risk of sudden arrhythmic death, WCD protected observation of LVEF progression and appraisal of competing risks of potential non-arrhythmic death may enable improved selection for beneficial ICD implantation.
Identifiants
pubmed: 32377784
doi: 10.1007/s00392-020-01657-2
pii: 10.1007/s00392-020-01657-2
pmc: PMC7806570
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
102-113Subventions
Organisme : Zoll CMS
ID : Research Grant
Commentaires et corrections
Type : ErratumIn
Références
Clin Res Cardiol. 2019 Aug;108(8):868-877
pubmed: 30689020
Clin Res Cardiol. 2020 Sep;109(9):1155-1164
pubmed: 32030498
Pacing Clin Electrophysiol. 2004 Jan;27(1):4-9
pubmed: 14720148
Clin Res Cardiol. 2020 Aug;109(8):1048-1059
pubmed: 32002631
J Am Coll Cardiol. 2013 Nov 19;62(21):2000-2007
pubmed: 23916930
J Am Heart Assoc. 2019 Mar 19;8(6):e011077
pubmed: 30845873
JAMA Cardiol. 2016 Aug 1;1(5):510-8
pubmed: 27434402
Europace. 2015 Nov;17(11):1601-87
pubmed: 26318695
Clin Cardiol. 2017 Aug;40(8):586-590
pubmed: 28333373
Circulation. 2016 Apr 26;133(17):1715-27
pubmed: 27022063
Pacing Clin Electrophysiol. 2018 Oct;41(10):1307-1313
pubmed: 29992590
N Engl J Med. 2004 Dec 9;351(24):2481-8
pubmed: 15590950
Clin Res Cardiol. 2018 Jan;107(1):70-75
pubmed: 28993851
Am J Cardiol. 2012 Mar 1;109(5):729-35
pubmed: 22176998
N Engl J Med. 2018 Sep 27;379(13):1205-1215
pubmed: 30280654
JACC Cardiovasc Imaging. 2016 Sep;9(9):1046-1055
pubmed: 27450871
J Am Coll Cardiol. 2016 Mar 15;67(10):1186-1196
pubmed: 26965540
Clin Res Cardiol. 2020 Jan;109(1):115-123
pubmed: 31236690
J Am Coll Cardiol. 2017 May 30;69(21):2606-2618
pubmed: 28545633
Circulation. 2016 Aug 30;134(9):635-43
pubmed: 27458236
J Am Coll Cardiol. 2010 Jul 13;56(3):194-203
pubmed: 20620738
Circulation. 2014 Aug 26;130(9):743-8
pubmed: 25074505
Europace. 2017 Mar 1;19(3):335-345
pubmed: 27702851
Clin Res Cardiol. 2019 Oct;108(10):1074-1082
pubmed: 30788621
Eur Heart J. 2013 Aug;34(29):2230-42
pubmed: 23729691
N Engl J Med. 2009 Oct 8;361(15):1427-36
pubmed: 19812399
J Am Heart Assoc. 2017 Jan 17;6(1):
pubmed: 28096098
Circ Arrhythm Electrophysiol. 2013 Feb;6(1):117-28
pubmed: 23275233
Clin Res Cardiol. 2019 May;108(5):477-486
pubmed: 30264282
JACC Clin Electrophysiol. 2017 Mar;3(3):243-250
pubmed: 29759518
Circulation. 2015 Oct 27;132(17):1613-9
pubmed: 26316618
Circ Heart Fail. 2016 Jul;9(7):
pubmed: 27413037
Clin Res Cardiol. 2017 Aug;106(8):582-589
pubmed: 28275862
Eur J Heart Fail. 2017 Mar;19(3):377-386
pubmed: 27905161
J Cardiovasc Electrophysiol. 2020 May;31(5):1009-1018
pubmed: 32083365
Curr Heart Fail Rep. 2018 Dec;15(6):368-375
pubmed: 30353399
N Engl J Med. 2016 Sep 29;375(13):1221-30
pubmed: 27571011
Eur J Heart Fail. 2014 Dec;16(12):1331-6
pubmed: 25371320